What is the global market size of the Hereditary Angioedema Treatment Market?

Global Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2021 and is poised to grow from USD 2.72 billion in 2022 to USD 10.39 billion by 2030, growing at a CAGR of 2.56% in the forecast period (2023-2030).

Hereditary Angioedema Treatment Market Size

Hereditary Angioedema Treatment Market Insights

Global Hereditary Angioedema Treatment Market size was valued at USD 2.7 billion in 2023 and is poised to grow from USD 2.77 billion in 2024 to USD 3.37 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2025-2032).

The key factor driving market expansion is the increased acknowledgment of treating rare disorders such as hereditary angioedema (HAE). According to the National Organization for Rare Disorders (NORD), the scenario is estimated to affect around 1 in 50,000 persons, with this illness affecting 1 in 150,000 people worldwide. Angioedema attacks are characterised by abrupt, often severe swelling in several areas of the body, including the abdomen, limbs, throat, and face. Many organisations are raising awareness about the diseases and their treatments, such as the US Hereditary Angioedema Association, a non-profit organisation dedicated to providing HAE sufferers with access to cutting-edge remedy alternatives and dependable, private help to deal with symptoms.

According to a survey done in the United States, physicians indicated improvements in HAE care in recent years, according to the study. Due to recent therapeutic improvements, documented cases of HAE have improved, reducing anxiety about adverse treatment effects, and high levels of patient satisfaction have been noted. According to a July 2020 paper titled 'Spectrum of diagnosis of hereditary angioedema: Seven case reports,' roughly 30,000-50,000 persons in India are affected. Dermatologists, gastroenterologists, and clinical allergists handle the majority of cases.

US Hereditary Angioedema Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

The global hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge. 'CSL Behring (Australia) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pharming Group N.V. (Netherlands) ', 'BioCryst Pharmaceuticals, Inc. (USA) ', 'Ionis Pharmaceuticals, Inc. (USA) ', 'Sanofi S.A. (France) ', 'Adverum Biotechnologies, Inc. (USA) ', 'KalVista Pharmaceuticals, Inc. (USA) ', 'Attune Pharmaceuticals, Inc. (USA) ', 'Arrowhead Pharmaceuticals, Inc. (USA) ', 'Amgen Inc. (USA) ', 'BioMarin Pharmaceutical Inc. (USA) ', 'Catalyst Biosciences, Inc. (USA) ', 'RUCONEST (Pharming Group N.V., Netherlands) ', 'Haegarda (CSL Limited, Australia) ', 'Firazyr (Shire plc, UK) ', 'Dyax Corp. (USA) ', 'Adverum Biotechnologies, Inc. (USA) ', 'Amgen Inc. (USA)'

Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.

Rising awareness of rare conditions and hereditary angioedema in recent years can be credited to the expansion of the global market. The primary factors driving the global market include novel therapeutics, pipeline medications, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE. The majority of pipeline medications are oral, due to which the oral method of administration is growing as a trend in the market. This approach is more convenient for patients and has fewer adverse effects. Companies are attempting to get into the rare illnesses industry with novel products in the pipeline. Due to the market expiration, these players may enter the hereditary angioedema treatment market.

North America dominated the global hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.